Delcath Systems, Inc. (NASDAQ:DCTH) Receives Consensus Rating of “Buy” from Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $19.83.

A number of brokerages recently issued reports on DCTH. Stephens began coverage on Delcath Systems in a research report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective for the company. Craig Hallum assumed coverage on shares of Delcath Systems in a research note on Friday, June 28th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, HC Wainwright upped their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, May 15th.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DCTH. AIGH Capital Management LLC acquired a new stake in shares of Delcath Systems in the fourth quarter valued at $4,918,000. ADAR1 Capital Management LLC purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $962,000. Worth Venture Partners LLC acquired a new position in shares of Delcath Systems during the fourth quarter worth about $1,224,000. Vivo Capital LLC increased its stake in shares of Delcath Systems by 94.9% during the first quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock worth $7,950,000 after buying an additional 811,555 shares during the period. Finally, Levin Capital Strategies L.P. raised its holdings in Delcath Systems by 22.5% in the fourth quarter. Levin Capital Strategies L.P. now owns 49,000 shares of the company’s stock valued at $204,000 after acquiring an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Price Performance

NASDAQ:DCTH opened at $8.19 on Friday. The company’s 50-day moving average is $7.80 and its two-hundred day moving average is $5.90. Delcath Systems has a 1-year low of $2.25 and a 1-year high of $9.18. The firm has a market capitalization of $227.60 million, a price-to-earnings ratio of -3.09 and a beta of 0.64.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, meeting analysts’ consensus estimates of ($0.43). The firm had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $3.70 million. Delcath Systems had a negative return on equity of 290.07% and a negative net margin of 1,080.72%. As a group, equities analysts anticipate that Delcath Systems will post -1.31 earnings per share for the current fiscal year.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.